Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals(US:VNDA) Prnewswire·2025-11-28 12:00Accessibility StatementSkip Navigation WASHINGTON, Nov. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness: Partial Clinical Hold Re-Review Timeline About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuti ...